RB-201 is a first-in-class bispecific ADC targeting tumors co-expressing HER2 and TROP-2.
HER2 (human epidermal growth factor receptor 2) is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Over-expression of this oncogene has been shown to play an important role in the development and progression of various aggressive types of cancer.
TROP-2 (trophoblast cell-surface antigen 2) is expressed in some normal tissues but is over-expressed in a range of cancers including breast, colorectal, pancreatic, gastric and ovarian, as well as oral squamous cell carcinoma. TROP-2 plays an important role in tumor cell proliferation, apoptosis, and invasion, thereby impacting the prognosis and treatment of cancer patients.
There is a high incidence of HER2 and TROP-2 co-expression in multiple solid tumors including breast, gastric, colorectal, esophagus, pancreatic, and non small cell lung cancers (NSCLC).
RB-201 demonstrates superior efficacy against a range of HER2high human tumors co-expressing TROP-2 in animal models than monospecific ADCs targeting the same surface molecules.
RB-201 also shows strong and durable anti-tumor activity in HER2low human tumors co-expressing TROP-2 which is better than that delivered by monospecific ADCs targeting the same surface molecules.
We are currently planning a ‘First in Man’ Phase Ia/b clinical trial in patients bearing solid tumors expressing HER2 and TROP-2.
MORE DETAILS CAN BE PROVIDED ON REQUEST